Tags

Type your tag names separated by a space and hit enter

Assessment of bioequivalence of rifampicin, isoniazid and pyrazinamide in a four drug fixed dose combination with separate formulations at the same dose levels.
Int J Pharm 2002; 233(1-2):169-77IJ

Abstract

Tuberculosis (TB) needs treatment with three to five different drugs simultaneously, depending on the patient category. These drugs can be given as single drug preparations or fixed dose combinations (FDCs) of two more drugs in a single formulation. World Health Organization and International Union against Tuberculosis and Lung Disease (IUATLD) recommend FDCs only of proven bioavailability. The relative bioavailability of rifampicin (RIF), isoniazid (INH) and pyrazinamide (PYZ) was assessed on a group of 13 healthy male subjects from a four drug FDC versus separate formulations at the same dose levels. The study was designed to be an open, crossover experiment. A total of nine blood samples each of 3 ml volume were collected over a period of 24-h. The concentrations of RIF, its main metabolite desacetyl RIF (DRIF), INH and PYZ in plasma were assessed by HPLC analysis. Pharmacokinetic parameters namely AUC(0-24), AUC(0-inf), C(max), T(max), were calculated and subjected to different statistical tests (Hauschke analysis, two way ANOVA, normal and log transformed confidence interval) at 90% confidence interval. In addition, elimination rate constant (K(el)) and absorption efficiencies for each drug were also calculated. It was concluded that four drugs FDC tablet is bioequivalent for RIF, INH and PYZ to separate formulation at the same dose levels.

Authors+Show Affiliations

Department of Phamaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Sector 67, S.A.S. Nagar 160 062, Punjab, India.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

11897421

Citation

Agrawal, Shrutidevi, et al. "Assessment of Bioequivalence of Rifampicin, Isoniazid and Pyrazinamide in a Four Drug Fixed Dose Combination With Separate Formulations at the Same Dose Levels." International Journal of Pharmaceutics, vol. 233, no. 1-2, 2002, pp. 169-77.
Agrawal S, Kaur KJ, Singh I, et al. Assessment of bioequivalence of rifampicin, isoniazid and pyrazinamide in a four drug fixed dose combination with separate formulations at the same dose levels. Int J Pharm. 2002;233(1-2):169-77.
Agrawal, S., Kaur, K. J., Singh, I., Bhade, S. R., Kaul, C. L., & Panchagnula, R. (2002). Assessment of bioequivalence of rifampicin, isoniazid and pyrazinamide in a four drug fixed dose combination with separate formulations at the same dose levels. International Journal of Pharmaceutics, 233(1-2), pp. 169-77.
Agrawal S, et al. Assessment of Bioequivalence of Rifampicin, Isoniazid and Pyrazinamide in a Four Drug Fixed Dose Combination With Separate Formulations at the Same Dose Levels. Int J Pharm. 2002 Feb 21;233(1-2):169-77. PubMed PMID: 11897421.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Assessment of bioequivalence of rifampicin, isoniazid and pyrazinamide in a four drug fixed dose combination with separate formulations at the same dose levels. AU - Agrawal,Shrutidevi, AU - Kaur,Kanwal Jit, AU - Singh,Inderjit, AU - Bhade,Shantaram R, AU - Kaul,Chaman Lal, AU - Panchagnula,Ramesh, PY - 2002/3/19/pubmed PY - 2002/4/10/medline PY - 2002/3/19/entrez SP - 169 EP - 77 JF - International journal of pharmaceutics JO - Int J Pharm VL - 233 IS - 1-2 N2 - Tuberculosis (TB) needs treatment with three to five different drugs simultaneously, depending on the patient category. These drugs can be given as single drug preparations or fixed dose combinations (FDCs) of two more drugs in a single formulation. World Health Organization and International Union against Tuberculosis and Lung Disease (IUATLD) recommend FDCs only of proven bioavailability. The relative bioavailability of rifampicin (RIF), isoniazid (INH) and pyrazinamide (PYZ) was assessed on a group of 13 healthy male subjects from a four drug FDC versus separate formulations at the same dose levels. The study was designed to be an open, crossover experiment. A total of nine blood samples each of 3 ml volume were collected over a period of 24-h. The concentrations of RIF, its main metabolite desacetyl RIF (DRIF), INH and PYZ in plasma were assessed by HPLC analysis. Pharmacokinetic parameters namely AUC(0-24), AUC(0-inf), C(max), T(max), were calculated and subjected to different statistical tests (Hauschke analysis, two way ANOVA, normal and log transformed confidence interval) at 90% confidence interval. In addition, elimination rate constant (K(el)) and absorption efficiencies for each drug were also calculated. It was concluded that four drugs FDC tablet is bioequivalent for RIF, INH and PYZ to separate formulation at the same dose levels. SN - 0378-5173 UR - https://www.unboundmedicine.com/medline/citation/11897421/Assessment_of_bioequivalence_of_rifampicin_isoniazid_and_pyrazinamide_in_a_four_drug_fixed_dose_combination_with_separate_formulations_at_the_same_dose_levels_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0378517301009395 DB - PRIME DP - Unbound Medicine ER -